Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Translation in Brief

Delivering Model T CARs

How delivery technologies could give CAR therapies their Model T moment

April 26, 2017 11:04 PM UTC

A Fred Hutchinson Cancer Research Center team believes its two chimeric antigen receptor (CAR) delivery platforms could lower immunological and financial costs enough to turn engineered immune cell therapies into widely accessible treatments. With two studies on their implant- and nanoparticle-based CAR technologies published in the last two weeks, the researchers are seeking industry partners to turn both platforms into therapeutics.

Matthias Stephan, the principal investigator behind the studies, told BioCentury his goal was to broaden the use of CAR and other cellular immunotherapies by developing versions of the technologies that don't require wiping out the patient's immune system or growing tens of millions of cells in culture...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article